(Q42223120)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

title

Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Abdolvahab Moradi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Shahryar Semnani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Seyed Younes Hosseini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Vakili M.A

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

author name string

Atefeh Saeedi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Amir Ghaemi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Ali Gorji

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Hoorieh Soleimanjahi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Ahmad Hosseinzadeh Adli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

publication date

22 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

page(s)

11-21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11262-014-1070-z

15 March 2020

exact match

0 references

cites work

Viral hepatitis C gets personal--the value of human genomics to public health

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Hepatitis C virus infection and related liver disease: the quest for the best animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Immunobiology and pathogenesis of viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Progress in the development of preventive and therapeutic vaccines for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Vaccination of chimpanzees against infection by the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Gene therapy. Safer and virus-free?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Gene therapy: trials and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Recombinant lambda-phage nanobioparticles for tumor therapy in mice models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Protection of mice by a λ-based therapeutic vaccine against cancer associated with human papillomavirus type 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Bacteriophage-mediated nucleic acid immunisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Enhancement of phage-mediated gene transfer by nuclear localization signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Immunization with hepatitis C virus core gene triggers potent T-cell response, but affects CD4+ T-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Genetic immunisation against hepatitis B using whole bacteriophage lambda particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

HCV variability, the immune system and resistance to antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11262-014-1070-Z

Comparison of a bacteriophage-delivered DNA vaccine and a commercially available recombinant protein vaccine against hepatitis B

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24752903

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11262-014-1070-Z

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

15 March 2020

1004263329

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24752903%20AND%20SRC:MED&resulttype=core&format=json